ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,827.04
-1.54%
US Tech 100
20,263.20
-1.69%
다우존스 지수
41,938.45
-1.63%
Bitcoin
94,337.05
-0.37%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. MorphoSys AG (MOR)

  7. MorphoSys AG (MOR) 뉴스

MOR

MorphoSys (MOR)

MorphoSys AG
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MOR
일자시간출처헤드라인심볼기업
2024/07/1305:59Business WireMorphoSys Announces Voluntary Delisting from the Nasdaq Global MarketNASDAQ:MORMorphoSys AG
2024/07/0821:03PR Newswire (US)Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law FirmNASDAQ:MORMorphoSys AG
2024/06/2015:47Business WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority ShareholdersNASDAQ:MORMorphoSys AG
2024/06/1100:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/06/0705:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/06/0523:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/06/0505:06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
2024/06/0423:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/3123:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2923:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2823:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2423:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2403:19Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
2024/05/2323:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2322:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/2123:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/1723:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/1723:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/1705:43Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
2024/05/1623:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/1523:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/05/1323:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
2024/04/3005:01Business WireMorphoSys AG Reports First Quarter 2024 Financial ResultsNASDAQ:MORMorphoSys AG
2024/04/1121:39Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisNASDAQ:MORMorphoSys AG
2024/03/1405:02Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
2024/02/0620:14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:MORMorphoSys AG
2023/12/1109:31Business WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyNASDAQ:MORMorphoSys AG
2023/11/2107:19Dow Jones NewsMorphoSys Trial for Blood-Cancer Treatment Reaches Primary EndpointNASDAQ:MORMorphoSys AG
2023/11/2106:30Business WireMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionNASDAQ:MORMorphoSys AG
2023/11/1606:01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
 검색 관련기사 보기:NASDAQ:MOR

최근 히스토리

AMEX
SPY
SPDR S&P 500
COIN
XRPUSD
Ripple
NYSE
BAC
Bank of America
NASDAQ
TSLA
Tesla
COIN
AVAXUSD
Avalanche
NYSE
CVX
Chevron
NASDAQ
AAPL
Apple
CCOM
SILVER
SILVER
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
USOTC
ADDYY
Adidas (QX)
FX
USDGBP
US Dollar vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유